Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 33057570.
- Also identified by DOI 10.1001/jamaoncol.2020.4749 and PMC identifier 7563661.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cohort study evaluates the association of early trastuzumab interruption with clinical outcomes in patients with <i>ERBB2</i>-positive breast cancer.
Medical subject headings
- Breast Neoplasms